Findings indicate T-cell depletion could improve outcomes in differentiated thyroid cancer by targeting CCR4.
Tregs were increased and activated in DTC tumor tissue, indicating that they play an important role in creating an immunosuppressive microenvironment in DTC. The results suggest that eTreg-depletion immunotherapy using an anti-CCR4 antibody (mogamulizumab) might be effective for treating DTC.
No takes yet. Share an insight, caveat, or question.
Sano et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: